Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT05533632
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Participants will receive semaglutide s.c. injection once weekly in a dose escalation manner for 24 weeks.

Study Details

This study is testing the safety and tolerability of subcutaneous semaglutide in participants with type 2 diabetes (T2D) in Chile. Participants will get a once-weekly subcutaneous injection of semaglutide in doses decided by the study doctor's criteria, according to participant's personal needs. The study will last for about 24 weeks. Participants will have 4 clinic visits and 2 phone calls. Participants will have 3 laboratory tests during the study (blood and urine samples).

Key Dates

Start date
Apr 25, 2022
Status verified
Sep 2025
Primary completion
Jan 18, 2024
Completion
Jan 18, 2024

Study Design

Enrollment
104 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide
    Participants will receive semaglutide subcutaneous (s.c.) injection once weekly in a dose escalation manner for 24 weeks: 0.25 milligrams (mg) (weeks 1 to 4), 0.5 mg (weeks 5 to 12) and 0.5 mg or 1.0 mg (weeks 13 to 24).

Primary Outcome Measure

Number of Adverse Events (AEs) [ Time Frame: From baseline (Day 1) up to 24 weeks ]

Related coverage on Hipa.ai

Related Studies